Lucid Group (LCID) October 7 2025 Stock Analysis: Gravity SUV Lifts Deliveries to Record High – Will Expiring Tax Credits Stall the Momentum?
28 October 2025
4 mins read

Lucid Motors (LCID) Stock Soars on Record EV Deliveries and Saudi Backing – Analysts Split on 2026 Outlook

  • LCID stock price (Oct. 28, 2025): Lucid Group shares traded around $18.60 by midday, up about 2–3% on the day Financialcontent after sliding to $18.10 (-2.06%) in the prior session Zacks. The stock has oscillated this week, underperforming the rising broader market on Monday but rebounding on Tuesday.
  • Record Q3 deliveries, but guidance trimmed: Lucid delivered 4,078 vehicles in Q3 2025, a ~47% year-over-year jump, though slightly below analyst consensus of ~4,286 Reuters. The company narrowed its full-year production forecast to 18,000–20,000 vehicles, down from 20k, implying a need for record Q4 output ts2.tech. This caution sparked an ~8% post-announcement drop (to ~$22) earlier in October ts2.tech.
  • Upcoming earnings (Nov. 5): Lucid will report Q3 financial results on November 5, with Wall Street expecting a net loss around $2.29 per share on ~$380 million revenue ts2.tech. That EPS would be a ~43% smaller loss than a year ago, reflecting delivery growth. Investors will watch if Lucid beats these estimates (its “Earnings ESP” is a modest +0.7% ahead of the report Yahoo) and whether it updates 2025 targets.
  • Saudi backing and expansion: Saudi Arabia’s Public Investment Fund (PIF) now owns ~58.4% of Lucid ts2.tech after providing over $8 billion in funding. In Q3, 1,000+ Lucid vehicles built in Arizona were shipped to Lucid’s new Jeddah plant for final assembly, part of Saudi’s plan to localize EV production ts2.tech. The Saudi government has also committed to buying up to 100,000 Lucid EVs over 10 years, bolstering Lucid’s long-term demand.
  • Partnerships and new markets: Lucid is forging strategic deals and expanding its reach. In a headline partnership, Uber invested $300 million in Lucid and agreed to purchase 20,000 of Lucid’s upcoming Gravity SUVs (with Nuro’s Level 4 autonomous tech) for a robotaxi fleet starting in 2026 ts2.tech. Lucid also began delivering the Gravity SUV in Canada this month, its first international deliveries Marketbeat, and opened new sales/service centers in California to grow its U.S. footprint. To boost brand awareness, Lucid even tapped NBA stars Jalen Brunson and Josh Hart in a marketing collaboration Financialcontent, blending EV innovation with pop culture.
  • Executive shake-up: Leadership has evolved in 2025 – co-founder Peter Rawlinson stepped down as CEO in February, transitioning to an advisory role. COO Marc Winterhoff now serves as Interim CEO, tasked with steering Lucid’s ramp-up and cost reduction efforts Wardsauto Wardsauto. A new CFO, Taoufiq Boussaid, also came aboard in Q1 Wardsauto. These changes underscore a focus on execution as Lucid scales production of the Gravity and develops a mid-size EV platform (targeting ~$50k price) for 2026 ts2.tech.
  • Analyst commentary and outlook:Analysts remain divided on Lucid’s prospects. The average 12-month price target is ~$25 (≈35% above current levels), but targets span from as low as $10 to as high as $73.50 Fintel – a huge discrepancy reflecting bulls’ and bears’ split views. Some analysts laud Lucid’s technology and Saudi backing, while others flag its steep losses and cash burn. Notably, Weiss Ratings recently assigned Lucid a D- (“Sell”) grade Marketbeat, citing fundamental concerns. A Motley Fool analysis cautioned that “this luxury EV maker still has a lot to prove” before it justifies a buy below $23 Financialcontent. On the bullish side, optimists point to Lucid’s record growth – deliveries up 46% – and strategic partnerships as signs of long-term potential.
  • Competitive landscape & EV market trends: Lucid operates in a fiercely competitive EV arena dominated by Tesla and crowded with startups like Rivian and Fisker. Rivian, for example, delivered 13,201 vehicles in Q3 2025 (3× Lucid’s volume) Yahoo and, like Lucid, it slightly trimmed its 2025 delivery guidance (~41.5k–43.5k units) amid industry headwinds Electrive. Tesla, while far larger (435,000+ Q3 deliveries), has been slashing prices to stoke demand – a strategy that crimped its margins and led to a “disappointing” profit plunge in Q3 that rattled EV investors Financialcontent. Meanwhile, Fisker is ramping up its Ocean SUV deliveries in the lower-priced segment, adding pressure at the entry-luxury end of the market. Sector-wide, there are emerging signs of EV demand softening after early adopter phases. Reuters notes that Lucid and its rivals “are bracing for a sharp drop in sales in [Q4] without the $7,500 [tax credit]” that expired in the U.S. last month Reuters. In fact, some experts warn that EV demand “may soon fall off a cliff” heading into 2026 Financialcontent if economic conditions tighten and incentives wane. Such macro trends could temper Lucid’s growth narrative in the near term.

The Road Ahead for Lucid (Q4 2025 – 2026)

Looking forward, Lucid’s Q4 execution and 2026 outlook will be critical. The company must prove it can convert its growing order book – including the Saudi government fleet orders and Uber robotaxi deal – into scalable production without draining its ~$4–5 billion cash reserve. Interim CEO Winterhoff has emphasized “aggressively reducing costs” and improving manufacturing efficiency Wardsauto, as Lucid aims for profitability in the coming years. Achieving the low end of its 18k delivery guidance this year will require more than 8,000 vehicles in Q4, over double any prior quarter’s output ts2.tech – a steep challenge even with a second shift now online.

On November 5, investors will dissect Lucid’s Q3 earnings call for clues on reservation trends, production ramp progress, and 2026 targets. Key metrics to watch include its revenue (expected to jump significantly on the Q3 delivery surge ts2.tech) and cash burn rate. Any update on the forthcoming mid-size EV model (due ~2026) could also sway sentiment, since a ~$50k offering would broaden Lucid’s addressable market beyond the ultra-luxury segment ts2.tech. Additionally, commentary on the competitive environment – e.g. Tesla’s price war and Rivian’s growth – will provide context on how Lucid plans to carve out market share.

Bottom line: Lucid Motors’ stock is at a crossroads. The company is making tangible strides – record deliveries, new models and markets, strong backing from Saudi Arabia – yet investors remain cautious amid hefty losses and industry uncertainties. In the near term, news catalysts like the Q3 earnings results, any updated guidance for 2025 deliveries, or fresh partnerships could drive volatility in LCID shares. Longer-term, much of Lucid’s fate (and its stock price in 2026 and beyond) hinges on execution: scaling production efficiently, stimulating sustained demand (especially post tax-credit), and managing its finances. With analysts starkly split on Lucid’s trajectory, Q4 2025 will be an important proving ground for whether this EV upstart can start closing the gap with expectations – or if skepticism will continue to cloud its valuation going into 2026.

Sources: Lucid Group investor news Wardsauto Wardsauto; Reuters Reuters Reuters; Zacks/Yahoo Finance Zacks Yahoo; TechStock² (ts2.tech) ts2.tech ts2.tech; Fintel analyst data Fintel; MarketBeat/Yahoo Finance news feed Financialcontent Financialcontent; Rivian and sector delivery reports Yahoo; Motley Fool analysis Financialcontent.

Stock Market Today

  • Pfizer Q4 Preview: Non-Oncology Segment Sales Outlook and Market Impact
    January 19, 2026, 11:10 AM EST. Pfizer (PFE) is scheduled to report Q4 and full-year 2025 earnings on Feb. 3. While oncology sales account for over 28% of revenues, investor focus also shifts to non-oncology segments including Primary Care and Specialty Care. Key non-oncology products include Eliquis anticoagulant, Prevnar vaccines, COVID-19 vaccine Comirnaty, and newer drugs like RSV vaccine Abrysvo and migraine treatment Nurtec. Eliquis alliance revenues are expected to rise to $2.1 billion despite generic pressures. Prevnar vaccine sales likely declined in the U.S. but increased internationally, estimated at $1.64 billion. COVID-19 medication sales fell due to narrower vaccine recommendations and lower infections. In Specialty Care, Vyndaqel sales remain strong at an estimated $1.66 billion, while Xeljanz and Enbrel may have weakened. Pfizer's stock dropped 2.5% in past year, underperforming the industry, but trades at a forward price/earnings ratio of 8.58, suggesting valuation appeal.
Nvidia’s $4 Trillion AI Stock Surge: Record Highs, Mega Deals & Bold Forecasts
Previous Story

Nvidia Stock Soars to Record Heights on AI Frenzy – Is $300 Next?

Visa (V) Stock Poised for a Surge? Crypto Pilot and Travel Deals Fuel Optimism
Next Story

Visa Stock Jumps on Earnings Beat and Dividend Hike – Analysts Bullish on $400 Target

Go toTop